Insulin Glargine in Type 2 Diabetes Mellitus

NCT ID: NCT00272077

Last Updated: 2009-12-07

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-04-30

Brief Summary

Primary objective:

To evaluate in explorative manner the fasting blood glucose (FBG) coefficient of variability (CV)calculated on SMBG values (SMBG : Self-Monitoring of Blood Glucose).

Secondary objectives:

The secondary objectives are the assessment of: changes in glycaemic control (HbA1C), frequency of hypoglycaemias, changes in weight, final insulin dose, changes in lipid parameters, changes in urinary albumin-to-creatinine ratio, profile of patient which best fits each of the algorithms with the dependent variable of change in HbA1C and independent variables of age, gender, race, tobacco use, diabetes complications, initial HbA1C, initial weight, duration of diabetes mellitus, general education and diabetes education.

Conditions

Diabetes Mellitus, Type 2

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

Insuline glargine

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of type 2 diabetes mellitus for at least 5 years;
• Treatment with oral antidiabetic drugs in fixed combination (Combo, i.e. glibenclamide 2.5 mg + metformin 400 mg, 2 or 3 tablets, at stable dose in the last 3 months);
• HbA1c >= 8% and <= 11%;
• Body mass index (BMI) > 27 and < 35 kg/m2;
• Willingness and demonstrated ability to inject insulin;
• Demonstrated ability and willingness to perform self-monitoring of blood glucose (SMBG);

Exclusion Criteria

• Patients diagnosed with type 1 insulin dependent diabetes;
• Patients with latent autoimmune diabetes of adults (LADA), defined as fasting C-peptide levels < 1 ng/ml;
• Cardiac status NYHA III-IV;
• Impaired renal function as shown by (but not limited to) serum creatinine >= 1.5 mg/dl for males or >= 1.4 mg/dl for females;
• Planned pregnancy, pregnant or lactating females;
• Failure to use adequate contraception (women of current reproductive potential only);
• Any current malignancy, previous breast cancer, or malignant melanoma within the past 5 years;
• Diagnosis of dementia
• Hypersensitivity to insulin or any of their components or to metformin;
• Current or previous insulin therapy other than during hospitalisations;
• Inability or unwillingness to continue metformin at study dosages throughout the study;
• Treatment with intermittent doses of systemic steroids or large doses of inhaled steroids for the past one year (fixed doses for the past 6 months is acceptable providing there is no plan to change the dosage regime);
• Stroke, Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG), Percutaneous Transluminal Coronary Angioplasty (PTCA), or Angina Pectoris within the last 12 months;
• History of drug or alcohol abuse;
• Receipt of an experimental drug or use of an experimental device within the 30 days prior to study entry;

• Minimum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

sanofi-aventis

Principal Investigators

PAIZIS GEORGES, MD

Role: STUDY_DIRECTOR

Sanofi

Other Identifiers

EudraCT # : 2004-002730-19

Identifier Type: -

Identifier Source: secondary_id

HOE901_3509

Identifier Type: -

Identifier Source: org_study_id